Race for a COVID-19 Vaccine: Will Emerging Economies Be Left Behind?
With 20m people infected globally and 735,000 virus-related deaths as of August 10, it is becoming increasingly clear that a vaccine is required for societies and economies to return to a sense of normality.
At present, researchers around the world are working on more than 150 different vaccines, with 26 already reaching the human trial stage.
The issue presents an interesting conundrum for emerging markets, amid concerns that many may miss out on early access to vaccines in favor of wealthier countries.
Photo courtesy of Bill Oxford.